NovaVive Inc., an animal health immunobiology company, announces that its immunotherapy for equine endometritis, Settle®, has received approval for sale in Canada from the Canadian Food Inspection Agency (CFIA). The product is expected to launch in the first quarter of this year.
Settle is manufactured using the NovaVive Mycobacterium cell wall fraction (MCWF) technology. It is also approved by regulators in the USA, Australia, New Zealand, and UAE as an aid in the treatment of equine endometritis caused by Streptococcus zooepidemicus, the hardest to treat cause of the disease. When administered into a mare, Settle stimulates her immune system to fight the infection.
Settle is backed by a significant amount of scientific research. Published data shows that it can be used to:
- Decrease pro-inflammatory cytokine production (IL-1β)
- Increase anti-inflammatory cytokine production (IL-10)
- Decrease fluid retention
- Decrease polymorphonuclear neutrophil (PMN) infiltration
- Decrease bacterial infiltration
- Increase conception at foal heat
- Treat endometrial cups
About NovaVive Inc.
NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with 5 regulator-approved products in the USA, 4 in Canada, 3 in New Zealand, and 2 each in Australia and the UAE.
One formulation has been developed as an anticancer therapy in dogs and horses. Other formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of bacterial diseases of horses and cattle or effectively treating viral equine respiratory disease.